derenofylline
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT00160134)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Adenosine A1 receptorANTAGONIST
ADORA1 antagonist
Phase 2 study terminated early, no reason given (PMID:21641345). Company aquired by Abbott, compound not on current pipeline.
Chemistry & pharmacology
Loading structure…
SMILES
OC1CCC(Nc2nc(-c3ccccc3)nc3[nH]ccc23)CC1- Mol. weight
- 308.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL592435 ↗
Also known as
- derenofylline
- derenofylline
- derenofylline
- slv320
- slv320
- slv-320
- slv-320
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00744341 | Phase 2 | Feb 1, 2009 | Solvay |
| NCT00160134 | Phase 2 | Jan 1, 2005 | Solvay |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Solvay | For profit | 2 | 2 | 1 | 2005 |
1 organizations
Page 1 / 1